Synonyms: 7E3 antibody | antiGPIIBIIIa | C7E3 | ReoPro®
abciximab is an approved drug (FDA (1994))
Compound class:
Antibody
Comment: Abciximab is a chimeric human-murine monoclonal antibody Fab (fragment antigen binding) fragment designed to target glycoprotein IIb/IIIa receptor, a key mediator of platelet aggregation and clot formation [2]. The invention of abciximab is covered by patent US5976532 [1], where its originating antibody is coded c7E3.
View more information in the IUPHAR Pharmacology Education Project: abciximab |
Classification | |
Compound class | Antibody |
Approved drug? | Yes (FDA (1994)) |
International Nonproprietary Names | |
INN number | INN |
7200 | abciximab |
Synonyms |
7E3 antibody | antiGPIIBIIIa | C7E3 | ReoPro® |
Database Links | |
Specialist databases | |
IMGT/mAb-DB | 146 |
Other databases | |
GtoPdb PubChem SID | 178103197 |
PubChem SID | 178103197 |
Search PubMed clinical trials | abciximab |
Search PubMed titles | abciximab |
Search PubMed titles/abstracts | abciximab |
Wikipedia | Abciximab |